Silo Pharma, Inc. Files 8-K with Updates
Ticker: SILO · Form: 8-K · Filed: Sep 10, 2024 · CIK: 1514183
| Field | Detail |
|---|---|
| Company | Silo Pharma, Inc. (SILO) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, corporate-update
TL;DR
Silo Pharma (SILO) filed an 8-K on Sept 10th, updating its corporate status and financials.
AI Summary
On September 10, 2024, Silo Pharma, Inc. filed an 8-K report detailing a Regulation FD Disclosure and Other Events. The filing also includes financial statements and exhibits. Silo Pharma, Inc. was formerly known as Uppercut Brands, Inc., Point Capital, Inc., and Gold Swap Inc.
Why It Matters
This 8-K filing provides important updates and disclosures for Silo Pharma, Inc., which could impact investor understanding of the company's current status and recent activities.
Risk Assessment
Risk Level: low — The filing is a standard 8-K report for corporate disclosures and does not appear to contain any immediate negative news or significant financial distress.
Key Players & Entities
- Silo Pharma, Inc. (company) — Registrant
- September 10, 2024 (date) — Date of earliest event reported
- Uppercut Brands, Inc. (company) — Former company name
- Point Capital, Inc. (company) — Former company name
- Gold Swap Inc (company) — Former company name
- Nevada (jurisdiction) — State of incorporation
- 001-41512 (identifier) — Commission File Number
- 677 N. Washington Boulevard (address) — Principal business address
- Sarasota, FL 34236 (address) — Principal business address
FAQ
What specific events are being disclosed under Regulation FD?
The filing indicates a Regulation FD Disclosure, but the specific details of the disclosure are not provided in the header information.
What types of financial statements and exhibits are included in the filing?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific content of these statements and exhibits is not detailed in the provided header.
When did Silo Pharma, Inc. change its name from Uppercut Brands, Inc.?
Silo Pharma, Inc. changed its name from Uppercut Brands, Inc. on August 8, 2019.
In which state is Silo Pharma, Inc. incorporated?
Silo Pharma, Inc. is incorporated in Nevada.
What is the Commission File Number for Silo Pharma, Inc.?
The Commission File Number for Silo Pharma, Inc. is 001-41512.
Filing Stats: 589 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2024-09-10 06:46:07
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share SILO The Nasdaq Stock Mar
Filing Documents
- ea0213917-8k_silopharma.htm (8-K) — 26KB
- ea021391702ex99-1_silo.htm (EX-99.1) — 25KB
- ex99-1_001.jpg (GRAPHIC) — 172KB
- ex99-1_002.jpg (GRAPHIC) — 322KB
- ex99-1_003.jpg (GRAPHIC) — 187KB
- ex99-1_004.jpg (GRAPHIC) — 235KB
- ex99-1_005.jpg (GRAPHIC) — 201KB
- ex99-1_006.jpg (GRAPHIC) — 244KB
- ex99-1_007.jpg (GRAPHIC) — 263KB
- ex99-1_008.jpg (GRAPHIC) — 282KB
- ex99-1_009.jpg (GRAPHIC) — 257KB
- ex99-1_010.jpg (GRAPHIC) — 182KB
- ex99-1_011.jpg (GRAPHIC) — 191KB
- ex99-1_012.jpg (GRAPHIC) — 231KB
- ex99-1_013.jpg (GRAPHIC) — 216KB
- ex99-1_014.jpg (GRAPHIC) — 238KB
- ex99-1_015.jpg (GRAPHIC) — 283KB
- ex99-1_016.jpg (GRAPHIC) — 243KB
- ex99-1_017.jpg (GRAPHIC) — 186KB
- ex99-1_018.jpg (GRAPHIC) — 134KB
- 0001213900-24-077111.txt ( ) — 5587KB
- silo-20240910.xsd (EX-101.SCH) — 3KB
- silo-20240910_lab.xml (EX-101.LAB) — 33KB
- silo-20240910_pre.xml (EX-101.PRE) — 22KB
- ea0213917-8k_silopharma_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. Reference is made to the disclosure under Item 8.01 below which is hereby incorporated in this Item 7.01 by reference.
01 Other Events
Item 8.01 Other Events. Silo Pharma, Inc. (the "Company") has made available a presentation (the "Presentation") management intends to use from time to time in presentations about the Company's operations and performance, including at the H.C. Wainwright 26th Annual Global Investment Conference on September 10, 2024 and will also be posted to the Company's website on September 10, 2024. The Presentation is filed as Exhibit 99.1 to this Current Report on Form 8-K ("Report") and incorporated herein by reference The information contained in the Presentation is summary information that should be considered in the context of the Company's filings with the Securities and Exchange Commission and other public announcements the Company may make by press release or otherwise from time to time. The Presentation speaks as of the date of this Report. While the Company may elect to update the Presentation in the future to reflect events and circumstances occurring or existing after the date of this Report, the Company specifically disclaims any obligation to do so. The Presentation contains forward-looking statements, and as a result, investors should not place undue reliance on these forward-looking statements.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Presentation 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) -1-
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. SILO PHARMA, INC. Date: September 10, 2024 By: /s/ Eric Weisblum Eric Weisblum Chief Executive Officer -2-